Want to hear the latest updates on the current clinical trials in #Parkinsons? 💭 Check out our interview with Fabrizio Stocchi of @SapienzaRoma from #ADPD2024: 👉 ​​ow.ly/LJgs50Rn33s #MovementDisorders #CTSM #Neurology #NeuroTwitter

In an interesting interview from #ADPD2024, Natalia Owen (@Cambridge_Uni) discusses her study looking at the comparative prognostic potential of various fluid biomarkers in #Huntingtonsdisease: 👉 ow.ly/4t4f50Rn2u3 #MovementDisorders #Neurology #NeuroTwitter

Reactive astrocytes spell trouble for #neurons, while microglia transform from protectors to slayers once plaques appear. Discover more about these findings shared during #ADPD2024 and shaping our understanding of AD.➡️ bit.ly/4d8WWv8 @alzforum #alzheimers #neuroscience

Did you know that all Gold Track registered delegates have exclusive access to the #ADPD2024 virtual platform until August 9, 2024?💻Rewatch the enlightening sessions and catch-up on all you might have missed during the conference back in March. - bit.ly/4aLPvIL

@GuilhermeGilMo1 @ClaudioGomesLab @cienciasulisboa @ULisboa_ @BioISI @Antonio27902425 We hope that it was a success. #ADPD2024

Missed out on sessions at #ADPD2024 in Lisbon? Don't worry, we've got you covered! 🎥✨ Gain exclusive access to the virtual platform until August 9, 2024, and catch up on all the insightful sessions with recordings from the conference. 💻 bit.ly/3Uai78M

lightning.health/news/managing-… #ParkinsonsDisease #PD #ParkinsonsAwareness #ParkinsonsAwarenessMonth #April #April2024 #Medical #ADPD2024 #PDAvengers #Parkinson #ParkinsonsExercise #Rehab #Wellness #Opioids #OpioidsCrisis #Anxiety #MentalHealth #Canada #Canadian #OnHealth

#ICYMI, we had a great time sponsoring & attending the AD/PD 2024 International Conference last month in Lisbon, Portugal! #TeamLantheus connected w/ experts from around the world on #Alzheimersdisease & other neurodegenerative disease research. #FindFightFollow #ADPD2024

🔬 Researchers are uncovering the intricate mechanisms behind how tau spreads within the brain, shedding new light on potential treatment avenues. Discover how proteins and astrocytes play pivotal roles in this process. Read more➡️ bit.ly/3VOdB0P #ADPD2024 @alzforum

On the heels of #ADPD2024, Andrea Lobo, Ph.D., of @parkinsonstory discusses the SHAPE Phase 2 #fosgonimeton results, it’s mechanism of action, and supporting preclinical data in her recent article. Read it here: bit.ly/4awTtoC

#ADPD2024 is already in the books but the excitement is still buzzing. ✨ 📸 Relive the vibrant energy and enlightening moments through the conference photos. ➡️ bit.ly/3PX89VL #alzheimers #parkinsons #dementia #endalz #neuroscience #neuroscientist #researcher

At the recent AD/PD meeting in Lisbon, there were some therapeutic contenders for targeting hard-to-reach pockets of tau that might show potential for the future. 🧠🔬 Take a look: bit.ly/43FIfeH #adpd2024 #Alzheimers #dementia

are you watching the market ?? chat.whatsapp.com/Lk5RwuF5tiDGaZ… #Xauusdgold #ADP #ADPd2024 #Fed #forexsignals

Hosted between 5-9 March, #ADPD2024 drew over 4,700 participants to Lisbon, sharing the latest advances in diagnosis, treatment and care. Our Director for Research @AngeBradshaw_AE, reports back on some of the scientific advances @adpdnet alzheimer-europe.org/news/18th-inte…

At the #ADPD2024, @AC_Immune_SA presented an industry symposium on the latest clinical advances in the diagnosis and treatment of alpha-synuclein pathologies, including an update of its phase 2 VacSYn trial assessing ACI-7104.056 for #PD. @adpdnet neurologylive.com/view/ac-immune…

📲 New data presented at the #ADPD2024 showed that automated vowel space metrics derived from smartphone speech samples exhibited good-to-excellent test-retest reliability in the detection of dysarthria in patients with #PD. @Roche @adpdnet neurologylive.com/view/pd-smartp…

What’s going on beyond amyloid-β in Alzheimer’s disease management bioworld.com/articles/706956 #biotech #pharma #ADPD2024